Cheng Sohanya Roshan 4

What Happened
Cheng Sohanya Roshan, EVP & Chief Commercial Officer of Karyopharm Therapeutics (KPTI), had 947 performance-based restricted stock units (PSUs) vest on May 13, 2026 (awarded at $0.00). The next day, 324 of those shares were sold in an open-market broker-assisted sale at $9.50 per share for proceeds of $3,078 to satisfy tax withholding. Net from the vesting event, Roshan retained 623 shares (947 vested − 324 sold).

Key Details

• Transaction dates and prices:
  • 2026-05-13: Award/acquisition of 947 shares @ $0.00 (PSUs vested)
  • 2026-05-14: Sale of 324 shares @ $9.50 = $3,078 (broker-assisted)
• Shares owned after transaction: Net increase of 623 shares from this vesting event (total holdings after the transaction not specified in the filing excerpt).
• Footnotes:
  • F1: The 947 shares are PSUs granted in Feb 2024, earned after achieving a clinical milestone (complete enrollment in the Phase 3 XPORT-EC-042 trial) and certified by the Compensation Committee on May 13, 2026.
  • F2: The 324-share sale was executed under a durable automatic sale instruction plan (adopted June 7, 2022) to cover withholding tax and was broker-assisted — not a discretionary trade.
• Filing: Report filed May 15, 2026 covering transactions on May 13–14; filing not indicated as late.

Context
This is primarily a compensation vesting event (PSUs earned) with a routine sale to cover taxes. Such tax-withholding sales under an automatic instruction plan are common and do not necessarily signal the insider’s view of the company’s prospects. Purchases or voluntary sales are generally more informative about sentiment than mandatory tax-withholding sales.